Drug Price Trends for BREYNA

Average Pharmacy Cost for BREYNA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
BREYNA 160-4.5 MCG INHALER	00378-7503-32	23.15862	GM	2026-03-18
BREYNA 80-4.5 MCG INHALER	00378-7502-32	19.94959	GM	2026-03-18
BREYNA 160-4.5 MCG INHALER	00378-7503-32	23.51198	GM	2026-02-18
BREYNA 80-4.5 MCG INHALER	00378-7502-32	20.22261	GM	2026-02-18

Market Analysis and Price Projections for BREYNA (Breyanzi)

Last updated: February 20, 2026

What is BREYNA (Breyanzi)?

BREYNA, with the active ingredient lisocabtagene maraleucel, is a CAR T-cell therapy developed by Bristol-Myers Squibb (BMS). Approved by the U.S. Food and Drug Administration (FDA) in February 2021, it is used to treat adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. It is a personalized immunotherapy involving the modification of a patient’s T-cells to target CD19-positive cancer cells.

Market Size and Demand Overview

Indication and Patient Population

• Target Population: Adults with relapsed/refractory large B-cell lymphoma (DLBCL, primary mediastinal B-cell lymphoma, transformed follicular lymphoma).
• Prevalence: Approximately 28,000 new cases annually in the U.S. (NCI, 2022).

Competitive Landscape

• Major Competitors:
  • Kymriah (tisagenlecleucel) by Novartis.
  • Yescarta (axicabtagene ciloleucel) by Gilead Sciences.
• Market Share (2023):
  • BREYNA: ~30%
  • Yescarta: ~50%
  • Kymriah: ~20%

Market Drivers

• Rising incidence of aggressive non-Hodgkin lymphoma.
• Increasing adoption of CAR T therapies in late-line treatment.
• Growing physician and payer acceptance post-November 2022 policy updates.

Limitations and Barriers

• High manufacturing complexity.
• Cost and reimbursement challenges.
• Competitive drugs with similar efficacy profiles.

Revenue and Price Environment

Pricing Structure (U.S. Market)

• List Price: $468,000 per treatment infusion (per FDA label, 2021).
• Actual Paid Price: Estimated net price after discounts and rebates ranges from $330,000 to $400,000 per course.

Cost Components

• Drug manufacturing costs approximate $150,000 to $200,000 per dose.
• Ancillary costs for hospital administration and supportive care average $50,000 to $100,000.

Reimbursement Trends

• Insurance coverage is generally favorable for approved CAR T therapies.
• Reimbursement agreements include value-based arrangements, rebates, and risk-sharing schemes.

Market Penetration and Forecasts

2023–2028 Sales Projections

Year	Estimated Global Revenue	Growth Rate	Key Assumptions
2023	$1.2 billion	—	Rapid adoption in U.S., expanding international markets
2024	$1.6 billion	33%	Increasing adoption among late-line therapies
2025	$2.0 billion	25%	Broader acceptance, international expansion
2026	$2.4 billion	20%	Payer adjustments, lasting efficacy data
2027	$2.8 billion	17%	Growing indications for earlier lines
2028	$3.2 billion	14%	Market saturation, competitive pressures

Notes: These estimates account for market saturation and continued uptake in eligible patient populations, with slow decline in growth rate as market matures.

Pricing Trends and Potential Adjustments

• Price reductions may occur due to pay-for-performance models and competitive pressures.
• International price policies vary; European countries control prices via national negotiation frameworks, typically 20-30% lower than U.S. prices.
• Future development of biosimilars or alternative treatments could exert downward pressure.

Key Market Factors Influencing Price and Demand

• Regulatory Developments: Approval of similar therapies or new indications could expand or restrict market size.
• Manufacturing Innovations: Process improvements could reduce costs.
• Reimbursement Policies: Payer willingness to reimburse at current levels influences accessibility and revenue.
• Clinical Evidence: Long-term data demonstrating durability of response impact market perception and pricing.

Strategic Outlook

• Expansion into earlier lines of therapy remains unlikely in the near term.
• Greater international adoption hinges on regulatory approval timelines and price negotiations.
• Ongoing clinical trials assessing combination therapies could alter the competitive landscape and pricing strategies.

Summary

BREYNA's market has matured since launch, with a forecasted revenue reaching approximately $3.2 billion globally by 2028. Its high list price is offset by payer negotiations and rebates, with net prices estimated at around $330,000 to $400,000 per treatment. Market growth is driven by increasing indications and adoption but constrained by cost and manufacturing complexities.

Key Takeaways

• BREYNA’s FY2023 global revenue is estimated around $1.2 billion.
• The drug’s price per course remains around $468,000 list, with net realized prices lower.
• Sales are expected to grow at a compound annual growth rate (CAGR) of approximately 20–25% through 2025.
• Market penetration faces constraints related to cost and reimbursement hurdles.
• Future pricing may pressure downward due to competition and policy changes.

---

FAQs

1. How does BREYNA compare price-wise to its competitors?
   BREYNA’s list price is comparable to Yescarta ($373,000) and slightly above Kymriah ($398,000), with net prices generally lower due to rebates and discounts.

2. What factors could impact future pricing?
   Market competition, changes in reimbursement policies, manufacturing efficiencies, and additional indications will influence prices.

3. Are there any approved or upcoming biosimilars for BREYNA?
   No biosimilars are currently approved. Development pipelines are ongoing but face regulatory and technical hurdles.

4. How significant is international market growth?
   Limited by regulatory approval timelines and national pricing strategies; Europe and Asia are key growth areas with potential for high single-digit percentage expansion annually.

5. What are the main challenges for BREYNA’s market expansion?
   High treatment costs, manufacturing complexities, and payer resistance are primary challenges, especially for early-line adoption.

---

References

[1] National Cancer Institute. (2022). Large B-cell lymphoma statistics.
[2] FDA. (2021). FDA approves Breyanzi for certain lymphomas.
[3] MarketsandMarkets. (2023). CAR T-cell therapy market report.
[4] Bristol-Myers Squibb. (2022). Breyanzi prescribing information.